|
SI2595980T1
(sl)
|
2010-07-22 |
2014-11-28 |
Gilead Sciences, Inc. |
Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
|
|
RU2016146365A
(ru)
*
|
2014-05-13 |
2018-06-19 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
|
|
TWI767201B
(zh)
|
2014-10-29 |
2022-06-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
US9637485B2
(en)
*
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
JP6435054B2
(ja)
*
|
2015-02-11 |
2018-12-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防のための新規２−オキソ−６，７−ジヒドロベンゾ［ａ］キノリジン−３−カルボン酸誘導体
|
|
JP6462155B2
(ja)
|
2015-05-04 |
2019-01-30 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
WO2017017042A1
(en)
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
SI3349758T1
(sl)
|
2015-09-16 |
2022-08-31 |
Gilead Sciences, Inc. |
Postopki za zdravljenje okužb z virusom arenaviridae
|
|
MX384799B
(es)
|
2016-02-19 |
2025-03-14 |
Novartis Ag |
Compuestos tetraciclicos de piridona como antivirales.
|
|
MX384836B
(es)
|
2016-03-07 |
2025-03-14 |
Enanta Pharm Inc |
Agentes antivirales contra la hepatitis b
|
|
MA45088A
(fr)
|
2016-05-27 |
2019-04-10 |
Gilead Sciences Inc |
Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JP2019521972A
(ja)
|
2016-06-10 |
2019-08-08 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
MA45496A
(fr)
*
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
CN109415368B
(zh)
*
|
2016-07-14 |
2021-04-30 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
WO2018022282A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Newave Pharmaceutical Inc. |
Novel therapeutic agents for the treatment of hbv infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
ES2906581T3
(es)
|
2016-09-02 |
2022-04-19 |
Gilead Sciences Inc |
Compuestos moduladores de los receptores tipo Toll
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
SG11201903042VA
(en)
|
2016-10-14 |
2019-05-30 |
Precision Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
|
WO2018083136A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydroisoquinolines and terahydronaphthyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2018083081A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP7068295B2
(ja)
|
2016-11-03 |
2022-05-16 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン
|
|
SG11201902944TA
(en)
|
2016-11-07 |
2019-05-30 |
Arbutus Biopharma Corp |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN109369640B
(zh)
*
|
2017-01-13 |
2020-03-27 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物的制备方法
|
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
AU2018223435B2
(en)
*
|
2017-02-23 |
2020-12-24 |
Fujian Akeylink Biotechnology Co., Ltd. |
Tri-cycle compound and applications thereof
|
|
KR102460968B1
(ko)
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
KR20190141747A
(ko)
|
2017-05-01 |
2019-12-24 |
길리애드 사이언시즈, 인코포레이티드 |
(S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
|
EP3675637A4
(en)
|
2017-08-28 |
2021-05-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
ES2940263T3
(es)
|
2017-10-05 |
2023-05-04 |
Glaxosmithkline Ip Dev Ltd |
Compuestos químicos
|
|
JP2021500013A
(ja)
|
2017-10-16 |
2021-01-07 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
|
|
WO2019084271A1
(en)
|
2017-10-25 |
2019-05-02 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHODS OF USE
|
|
CN111315749A
(zh)
|
2017-11-17 |
2020-06-19 |
诺华股份有限公司 |
新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
|
|
US10428070B2
(en)
|
2017-12-06 |
2019-10-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US10723733B2
(en)
|
2017-12-06 |
2020-07-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019123340A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
JP2021507906A
(ja)
*
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
WO2019122393A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Bayer Aktiengesellschaft |
Hydroxyisoxazolines and derivatives thereof
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
MX2020008404A
(es)
|
2018-02-13 |
2020-09-25 |
Gilead Sciences Inc |
Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
|
|
CN111788204B
(zh)
|
2018-02-26 |
2023-05-05 |
吉利德科学公司 |
作为hbv复制抑制剂的取代吡咯嗪化合物
|
|
CN111801331A
(zh)
|
2018-02-28 |
2020-10-20 |
诺华股份有限公司 |
吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
|
|
TWI801517B
(zh)
|
2018-03-12 |
2023-05-11 |
加拿大商愛彼特生物製藥公司 |
經取代的2-吡啶酮三環化合物、其類似物及其使用方法
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
AU2019252441A1
(en)
|
2018-04-12 |
2020-10-22 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
|
ES3035911T3
(en)
|
2018-04-19 |
2025-09-11 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
CN112567033A
(zh)
|
2018-07-03 |
2021-03-26 |
豪夫迈·罗氏有限公司 |
用于调节Tau表达之寡核苷酸
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US12128044B2
(en)
|
2018-08-28 |
2024-10-29 |
Sunshine Lake Pharma Co., Ltd. |
Fused tricyclic compounds and uses thereof in medicine
|
|
CN112955142A
(zh)
|
2018-09-21 |
2021-06-11 |
英安塔制药有限公司 |
官能化杂环化合物作为抗病毒剂
|
|
US11447498B2
(en)
|
2018-09-30 |
2022-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Fused tetracyclic compounds and uses thereof in medicine
|
|
JP7158577B2
(ja)
|
2018-10-24 |
2022-10-21 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｐｄ－１／ｐｄ－ｌ１阻害剤
|
|
LT3873903T
(lt)
|
2018-10-31 |
2024-05-10 |
Gilead Sciences, Inc. |
Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
IL283190B2
(en)
|
2018-11-21 |
2025-08-01 |
Enanta Pharm Inc |
Functionalized heterocycles as antiviral agents
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN114014854B
(zh)
*
|
2019-01-08 |
2023-04-07 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
JP7617020B2
(ja)
|
2019-04-24 |
2025-01-17 |
チルドレンズ メディカル センター コーポレイション |
Ｐａｐｄ５阻害剤およびその使用方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US11760755B2
(en)
|
2019-06-04 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
JP7295283B2
(ja)
|
2019-06-25 |
2023-06-20 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
|
|
WO2021007488A1
(en)
|
2019-07-11 |
2021-01-14 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
WO2021055425A2
(en)
|
2019-09-17 |
2021-03-25 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
CR20220129A
(es)
|
2019-09-30 |
2022-05-06 |
Gilead Sciences Inc |
Vacunas para vhb y métodos de tratamiento de vhb
|
|
EP4069729B1
(en)
|
2019-12-06 |
2025-01-22 |
Precision BioSciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
PE20230376A1
(es)
|
2019-12-24 |
2023-03-06 |
Carna Biosciences Inc |
Compuestos moduladores de la diacilglicerol quinasa
|
|
CN114641299A
(zh)
|
2020-01-27 |
2022-06-17 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
CN118994170A
(zh)
|
2020-03-12 |
2024-11-22 |
吉利德科学公司 |
制备1'-氰基核苷的方法
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
TW202421168A
(zh)
|
2020-03-20 |
2024-06-01 |
美商基利科學股份有限公司 |
4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
|
|
WO2021207049A1
(en)
|
2020-04-06 |
2021-10-14 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
WO2021228213A1
(zh)
*
|
2020-05-15 |
2021-11-18 |
福建广生堂药业股份有限公司 |
包含三并环类化合物的组合及其在制备治疗hbv药物中的应用
|
|
EP4157272B1
(en)
|
2020-05-29 |
2025-07-02 |
Gilead Sciences, Inc. |
Remdesivir for the treatment of viral infections
|
|
US11939347B2
(en)
|
2020-06-24 |
2024-03-26 |
Gilead Sciences, Inc. |
1′-cyano nucleoside analogs and uses thereof
|
|
CN116194144A
(zh)
|
2020-08-07 |
2023-05-30 |
吉利德科学公司 |
膦酰胺核苷酸类似物的前药及其药物用途
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
CA3188373A1
(en)
|
2020-08-24 |
2022-03-03 |
Scott E. Lazerwith |
Phospholipid compounds and uses thereof
|
|
SI4204421T1
(sl)
|
2020-08-27 |
2024-07-31 |
Gilead Sciences, Inc., |
Spojine in postopki za zdravljenje virusnih okužb
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
US12427150B2
(en)
|
2021-05-26 |
2025-09-30 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1′-cyano substituted carba-nucleoside analogs
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11926628B2
(en)
|
2021-06-23 |
2024-03-12 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
US11999733B2
(en)
|
2021-06-23 |
2024-06-04 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2023023527A1
(en)
|
2021-08-18 |
2023-02-23 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
EP4320128A1
(en)
|
2022-03-02 |
2024-02-14 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2023167938A1
(en)
|
2022-03-02 |
2023-09-07 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
AU2023227850A1
(en)
|
2022-03-03 |
2024-09-26 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
KR20240155327A
(ko)
|
2022-03-03 |
2024-10-28 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물 및 이의 제조와 사용 방법
|
|
WO2023239665A1
(en)
|
2022-06-06 |
2023-12-14 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections including sars-cov-2
|
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
US20240309028A1
(en)
|
2023-02-16 |
2024-09-19 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
WO2025049699A1
(en)
|
2023-08-31 |
2025-03-06 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250084088A1
(en)
|
2023-08-31 |
2025-03-13 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250099476A1
(en)
|
2023-09-06 |
2025-03-27 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
WO2025072641A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|